Rl. White et al., CARDIOPULMONARY TOXICITY OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 IN199 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CELL CARCINOMA, Cancer, 74(12), 1994, pp. 3212-3222
Background. Administration of recombinant interleukin-2 (rIL-2) can me
diate tumor regression in patients with metastatic melanoma and renal
cell carcinoma. In response to recent FDA approval of high dose rIL-2
for use in renal cell carcinoma, the authors recent experience with th
e cardiopulmonary toxicity associated with high dose IL-2 therapy is r
eviewed. Methods. The treatment courses of all patients receiving high
dose intravenous holus rIL-2 from January, 1988, until December, 1992
, were evaluated for cardiopulmonary toxicity. Results. One hundred ni
nety-nine patients received 310 courses of treatment. There were no tr
eatment-related deaths. Respiratory distress occurred in 3.2% of the c
ourses, requiring intubation in one patient. Three obtunded patients w
ere endotracheally intubated for airway control. Arrhythmias occurred
in 6% of the courses (18 patients) with hypotension developing in two
of the 199 patients as a result. Eleven of these patients were retreat
ed and recurrent atrial fibrillation developed in two. One episode of
significant ventricular tachycardia was noted. Hypotension occurred in
53% of courses; no patients developed hypotension unresponsive to vas
opressors. There were no myocardial infarctions; however, 2.5% of pati
ents experienced elevated creatine phosphokinase levels associated wit
h elevated MB isoenzymes attributed to cardiac toxicity. Only one of t
hese patients developed symptoms. Response rates of 19.6% and 15.7% we
re noted in patients with renal cell carcinoma and melanoma, respectiv
ely. Hypotension requiring vasopressors was associated with a signific
antly improved rate of response in patients with melanoma compared wit
h patients not requiring vasopressors (23.2% vs. 6.5%, P-2 = 0.037). C
onclusions. Although high dose intravenous rIL-2 therapy can be associ
ated with cardiopulmonary toxicity, toxic side effects generally are n
ot severe and are rapidly reversible.